Research Topics
| A PollackSummaryAffiliation: Fox Chase Cancer Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: an analysis of RTOG 8610A Pollack
Department of Radiation Oncology, Fox Chase Cancer Center, and Radiation Therapy Oncology Group, Philadelphia, PA 19111, USA
J Clin Oncol 21:1238-48. 2003..The protocol treatment randomization was RT alone versus RT plus short-course (approximately 4 months) neoadjuvant and concurrent total androgen blockade (RT+TAB)...
Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapyAlan Pollack
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 57:19-23. 2003..However, little evidence is available to show that BF is associated with death for patents with prostate cancer treated with radiotherapy. We examined the relationship between BF and death from prostate cancer...
Radiation therapy dose escalation for prostate cancer: a rationale for IMRTAlan Pollack
Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
World J Urol 21:200-8. 2003..The results of dose escalation, the ability of IMRT to reduce rectal and bladder exposure to high radiation doses and the use of new imaging methods to more accurately target the prostate are described...
Prostate cancer radiotherapy dose response: an update of the fox chase experienceAlan Pollack
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
J Urol 171:1132-6. 2004....
Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trialAlan Pollack
Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
Int J Radiat Oncol Biol Phys 54:677-85. 2002..These issues were investigated in a cohort of men with Stage T1-T3 prostate cancer who were randomized to receive between 70 Gy and 78 Gy and were prospectively biopsied at about 2 years after the completion of radiotherapy (RT)...
Impact of androgen deprivation therapy on survival in men treated with radiation for prostate cancerAlan Pollack
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Urology 60:22-30; discussion 30-1. 2002..The results with long-term ADT are much more convincing than short-term ADT, and, as a consequence, 2 to 3 years are recommended...
Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02A Pollack
Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111 2497, USA
J Clin Oncol 22:2133-40. 2004....
Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trialAlan Pollack
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
Int J Radiat Oncol Biol Phys 53:1097-105. 2002..A randomized radiotherapy dose escalation trial was undertaken between 1993 and 1998 to compare the efficacy of 70 vs. 78 Gy in controlling prostate cancer...
Lack of prostate cancer radiosensitization by androgen deprivationA Pollack
Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Int J Radiat Oncol Biol Phys 51:1002-7. 2001..Animal model studies have provided suggestive evidence that AD sensitizes cells to radiation, but this mechanism is difficult to confirm conclusively in vivo. This question was investigated in LNCaP cells grown in vitro...
Mindless or mindful? Radiation oncologists' perspectives on the evolution of prostate cancer treatmentAlan Pollack
Department of Radiation Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
Urol Clin North Am 30:337-49, x. 2003..In summary, advances in radiation oncology have led to significant gains in prostate cancer control. Clinical prognostic factor-based patient selection is central to the optimization of outcome...
Stereotactic IMRT for prostate cancer: dosimetric impact of multileaf collimator leaf width in the treatment of prostate cancer with IMRTL Wang
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
J Appl Clin Med Phys 5:29-41. 2004..78). In conclusion, the use of the mMLC for IMRT of the prostate resulted in significant improvement in the DVH parameters of the prostate and critical organs, which may improve the therapeutic ratio...
Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancerA Pollack
Departments of Radiation Oncology, Biostatistics, Urology, and Radiation Physics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 18:3904-11. 2000..To determine the effect of radiotherapy dose on prostate cancer patient outcome and biopsy positivity in a phase III trial...
Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancerG K Zagars
Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Urology 58:233-9. 2001..The addition of prostatic radiation to ablation resulted in substantial and significant improvement in disease control and patient survival...
External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA eraA Pollack
Department of Radiation Oncology, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
Int J Radiat Oncol Biol Phys 48:507-12. 2000..To characterize the relationship of radiotherapy dose to prostate cancer patient outcome, with an emphasis on the influence of pretreatment prognostic variables...
Clinical implementation of intensity-modulated tangential beam irradiation for breast cancerJ S Li
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Med Phys 31:1023-31. 2004..The IMRT technique has been proven practical for breast treatment clinically. The results showed that tangential IMRT improved the dose homogeneity in the breast and reduced the dose to the lung and heart...
Dosimetric evaluation of MRI-based treatment planning for prostate cancerL Chen
Radiation Oncology Department, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Phys Med Biol 49:5157-70. 2004..The difference in the target dose between CT- and MRI-based plans using homogeneous geometry was within 2.5%. Our results suggest that MRI-based treatment planning is suitable for radiotherapy of prostate cancer...
Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiationP J Colletier
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
Int J Radiat Oncol Biol Phys 48:1507-12. 2000..The objective was to determine if this vector sensitizes cells to radiation independently of their p53 status...
Daily target localization for prostate patients based on 3D image correlationK Paskalev
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Phys Med Biol 49:931-9. 2004..The impact of image noise on the performance of the algorithm has been tested. The results show that the algorithm accurately adjusts for target positional changes even with Gaussian noise levels as high as 20% inserted...
Treatment planning using a dose-volume feasibility search algorithmG Starkschall
Department of Radiation Physics, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
Int J Radiat Oncol Biol Phys 49:1419-27. 2001..In contrast to a search for the "best" plan, this approach can quickly determine feasibility and point out the most restrictive of the predetermined constraints...
Simultaneous estimation of T(G2+M), T(S), and T(pot) using single sample dynamic tumor data from bivariate DNA-thymidine analogue cytometryR A White
Department of Biomathematics, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
Cytometry 41:1-8. 2000..Inspection of the measured dynamic quantities, relative movement [RM(t)], fractions of labeled divided and undivided cells (f(lu)(t) and f(ld)(t)) suggests that T(G2+M), T(S), and T(pot) can be determined simultaneously...
Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancerN Taylor
Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
Int J Radiat Oncol Biol Phys 56:755-63. 2003..Because of the potential confounding factors, direct comparisons of ART and SRT are problematic; however, ART is extremely effective and offers the surest approach for maintaining biochemical control...
Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institutionP W Pisters
Sarcoma Center, The University of Texas M D Anderson Cancer Center, Houston 77030 4195, USA
J Clin Oncol 15:3481-7. 1997..To review a single institution's long-term results with doxorubicin-based preoperative chemotherapy for American Joint Committee on Cancer (AJCC) stage IIIB extremity soft tissue sarcoma (STS)...
Radiotherapy for stage II testicular seminomaG K Zagars
Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
Int J Radiat Oncol Biol Phys 51:643-9. 2001..CONCLUSIONS: PLSCI significantly diminishes the likelihood of relapse for Stage IIA, IIB, and IIC seminoma (mass <or=10 cm)...
Prevalence and patterns of self-initiated nutritional supplementation in men at high risk of prostate cancerR G Uzzo
The Department of Urology, Fox Chase Cancer Centre, Temple University School of Medicine, 333 Cottman Avenue, Philadelphia, PA 19111 2497, USA
BJU Int 93:955-60. 2004....
Prostate cancer gene therapy and the role of radiationJ M Kaminski
Department of Radiation Oncology, Fox Chase Cancer Center, 7701 Burolme Avenue, Philadelphia, PA 19111, USA
Cancer Treat Rev 28:49-64. 2002..With further technological advances in radiation therapy, gene therapy, and the understanding of prostate cancer biology, gene therapy will potentially have an important role in prostate cancer therapy...
Longitudinal associations among quality of life and its predictors in patients treated for prostate cancer: the moderating role of ageMichael Diefenbach
Urology and Oncological Sciences, Mount Sinai School of Medicine, New York, NY10029 6574, USA
Psychol Health Med 13:146-61. 2008..Among older patients (>68 years old, n = 192), lower levels of distress were associated with higher levels of functional QOL, and longer expected survival time was associated with better functional and physical QOL...
Activated STAT3 as a correlate of distant metastasis in prostate cancer: a secondary analysis of Radiation Therapy Oncology Group 86-10Javier F Torres-Roca
Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
Urology 69:505-9. 2007....
The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancerAlexandra L Hanlon
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 67:1082-7. 2007..To investigate the prognostic utility of the proportion of prostate biopsy tissue containing Gleason pattern 4 or 5 (GP4/5) after definitive radiotherapy (RT) for prostate cancer...
Radiation dose and late failures in prostate cancerPeter B Morgan
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
Int J Radiat Oncol Biol Phys 67:1074-81. 2007..To quantify the impact of radiation dose escalation on the timing of biochemical failure (BF) and distant metastasis (DM) for prostate cancer treated with radiotherapy (RT) alone...
Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancerAndre Konski
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 66:408-15. 2006....
Target localization for post-prostatectomy patients using CT and ultrasound image guidanceKamen Paskalev
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
J Appl Clin Med Phys 6:40-9. 2005..However, ultrasound alignments performed without the use of a template deteriorated patient positioning for two out of three patients, demonstrating that the use of a CT template was beneficial even at small initial displacements...
Parameters for treatment decisions for salvage radiation therapyShelly Bowers Hayes
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
J Clin Oncol 23:8204-11. 2005..These factors should be used as a guide to the options of local therapy alone (RT), local therapy plus systemic therapy (typically androgen deprivation therapy), and systemic therapy alone...
Is 6 months of androgen suppression therapy plus radiotherapy of benefit in patients with localized prostate cancer?Alan Pollack
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Nat Clin Pract Oncol 2:12-3. 2005
Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trialAlan Pollack
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 64:518-26. 2006..The dosimetry and acute toxicity are described in the first 100 men enrolled in a randomized trial...
Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancerMark K Buyyounouski
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 63:1455-62. 2005..To compare several characteristics of alternative definitions of biochemical failure (BF) in men with extended follow-up after radiotherapy (RT) with or with androgen deprivation therapy (ADT) for prostate cancer...
What dose of external-beam radiation is high enough for prostate cancer?Thomas N Eade
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 68:682-9. 2007..To quantify the radiotherapy dose-response of prostate cancer, adjusted for prognostic factors in a mature cohort of men treated relatively uniformly at a single institution...
Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapyMary Feng
Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109 0010, USA
Int J Radiat Oncol Biol Phys 68:1417-23. 2007..To determine the rate and magnitude of late genitourinary (GU) and gastrointestinal (GI) toxicities after salvage or adjuvant radiotherapy (RT) for prostate cancer, and to determine predictive factors for these toxicities...
Racial differences in CYP3A4 genotype and survival among men treated on Radiation Therapy Oncology Group (RTOG) 9202: a phase III randomized trialMack Roach
Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA
Int J Radiat Oncol Biol Phys 69:79-87. 2007..To understand how variation in CYP3A4 correlated with outcomes, a retrospective examination of the CYP3A4 *1B genotype was performed on men treated with Radiation Therapy Oncology Group (RTOG) 92-02...
A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implantThomas N Eade
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
Int J Radiat Oncol Biol Phys 71:338-45. 2008..To compare the toxicity and biochemical outcomes of intensity-modulated radiation therapy (IMRT) and (125)I transperineal permanent prostate seed implant ((125)I) for patients with low-risk prostate cancer...
How can men destined for biochemical failure after androgen deprivation and radiotherapy be identified earlier?David J D'Ambrosio
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
Int J Radiat Oncol Biol Phys 70:1487-91. 2008..This study sought to determine whether the initial PSA increase from undetectable after completion of all treatment predicts for eventual biochemical failure (BF)...
The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancerMatthew C Abramowitz
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
Cancer 112:55-60. 2008..The objective of the current study was to compare ASTRO and Phoenix BF estimates as determinants of distant metastasis (DM), cause-specific mortality (CSM), and overall mortality (OM)...
Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancerDeborah A Kuban
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Int J Radiat Oncol Biol Phys 70:67-74. 2008..To report the long-term results of a randomized radiotherapy dose escalation trial for prostate cancer...
Comparing computed tomography localization with daily ultrasound during image-guided radiation therapy for the treatment of prostate cancer: a prospective evaluationSteven J Feigenberg
Fox Chase Cancer Center, Department of Radiation Oncology, Philadelphia, Pennsylvania 19111, USA
J Appl Clin Med Phys 8:2268. 2007..The isocenter shifts generated by using a CT unit in the treatment room correlate highly with shifts produced by the BAT Ultrasound system...
Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202Mingxin Che
Department of Pathology, Wayne State University, Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA
Int J Radiat Oncol Biol Phys 69:1117-23. 2007....
Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivoRadka Stoyanova
Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 68:1151-60. 2007..To test the effects of antisense (AS)-MDM2 alone and with androgen deprivation (AD), radiotherapy (RT), and AD + RT on wild-type LNCaP cells in an orthotopic in vivo model...
Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202Arnab Chakravarti
Massachusetts General Hospital Harvard Medical School, Department of Radiation Oncology, Boston, MA 02114, USA
J Clin Oncol 25:3082-9. 2007..In the present study, we examined the prognostic value of p16 expression in men with locally advanced prostate cancer who were enrolled on Radiation Therapy Oncology Group protocol 9202...
Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02Li Yan Khor
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Clin Cancer Res 13:3585-90. 2007..A follow-up investigation was carried out here in more contemporary high-risk men treated on Radiation Therapy Oncology Group 92-02 with STAD+RT or long-term AD+RT (LTAD+RT)...
Magnetic resonance-based treatment planning for prostate intensity-modulated radiotherapy: creation of digitally reconstructed radiographsLili Chen
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 68:903-11. 2007....
Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapyPeter B Morgan
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
Cancer 110:68-80. 2007..The authors hypothesized that early failures due to subclinical micrometastasis at presentation could be differentiated from late failures due to local persistence...
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomyAndrew J Stephenson
Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, OH 44195 0001, USA
J Clin Oncol 25:2035-41. 2007..We developed a nomogram to predict the probability of cancer control at 6 years after SRT for PSA-defined recurrence...
Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma?Stephen F Andrews
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Cancer 104:299-304. 2005..There are limited data on the consequences of radiation treatment delay. The purpose of the current study was to evaluate the effect of time to treatment (TTT) on outcomes...
Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapySteven J Feigenberg
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 62:397-405. 2005..To determine whether the use of androgen deprivation (AD) increases late morbidity when combined with high-dose three-dimensional conformal radiation therapy (3D-CRT)...
Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivationMark K Buyyounouski
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
Int J Radiat Oncol Biol Phys 61:1291-8. 2005..The American Society of Therapeutic Radiation Oncology definition for biochemical failure overestimates BF in 20-30% after RT+AD compared to 5% after RT alone...
Hazards of dose escalation in prostate cancer radiotherapyDeborah Kuban
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Int J Radiat Oncol Biol Phys 57:1260-8. 2003..To assess the benefit of escalating the dose in definitive prostate cancer radiotherapy vs. the associated risk of complications...
Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation studyDarren J Little
Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
Urology 62:707-13. 2003..Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased...
A method for increased dose conformity and segment reduction for SMLC delivered IMRT treatment of the prostateRobert A Price
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 57:843-52. 2003..The focus of this work is to develop a practical planning method that results in increased dose conformity and reduced treatment time for segmental multileaf collimation (sMLC) based intensity-modulated radiation therapy (IMRT) delivery...
Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapyDidier Cowen
Department of Experimental Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
Clin Cancer Res 8:1148-54. 2002..This prognostic factor was equally valuable for patients diagnosed by TURP or needle biopsy...
Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate cancer?Khanh H Nguyen
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 57:377-83. 2003....
Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and IIJeff M Michalski
Department of Radiation Oncology, Washington University, St Louis, MO 63110, USA
Int J Radiat Oncol Biol Phys 56:192-8. 2003..To evaluate the rates of low-grade late effects in patients treated for prostate cancer on Radiation Therapy Oncology Group (RTOG) 9406...
Treatment of prostate cancer with regional lymph node (N1) metastasisAlan Pollack
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Semin Radiat Oncol 13:121-9. 2003..Patients with a 10-year life expectancy should be treated aggressively with long-term AD combined with either EBRT or RP...
Hazard rates of disease progression after external beam radiotherapy for clinically localized carcinoma of the prostateCharles J Rosser
Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
J Urol 169:2160-5. 2003..Patients are at slight but persistent risk for biochemical failure more than 5 years after treatment. Hazard rate calculations beyond the median followup of 4 years can underestimate the true hazard...
Modifying the American Society for Therapeutic Radiology and Oncology definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3-dimensional conformal radiation therapy aloneEric M Horwitz
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
J Urol 169:2153-7; discussion 2157-9. 2003..Additional analysis with large numbers of patients from multiple institutions is necessary to determine the point...
A call for more with a desire for less: pelvic radiotherapy with androgen deprivation in the treatment of prostate cancerAlan Pollack
J Clin Oncol 21:1899-901. 2003
Is intraoperative nomogram-based overplanning of prostate implants necessary?WARREN D D'SOUZA
Division of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
Int J Radiat Oncol Biol Phys 56:462-7. 2003..Several investigators have described intraoperative planning of prostate implants based on a nomogram. The aim of this work was to investigate the adequacy of the nomogram in predicting the total activity necessary for optimal dosimetry...
Predictors of preferences and utilities in men treated with 3D-CRT for prostate cancerDeborah Watkins Bruner
Department of Population Science, Fox Chase Cancer Center, Philadelphia, PA, USA
Int J Radiat Oncol Biol Phys 58:34-42. 2004..To assess the preferences and utilities for prostate cancer health state scenarios of men treated with three-dimensional conformal radiotherapy and the predictors of treatment preferences...
Short-term androgen deprivation and PSA doubling time: their association and relationship to disease progression after radiation therapy for prostate cancerAlexandra L Hanlon
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 58:43-52. 2004....
What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?Steven J Feigenberg
Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 61:1003-10. 2005..The purpose of this study was to determine what pretreatment (initial) PSA (iPSA) level, if any, warrants the addition of long-term androgen deprivation in the PSA era...
Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvementRojymon Jacob
Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 61:695-701. 2005..These data suggest that the primary tumor takes precedence over lymph node coverage or the use of STAD. Doses >70 Gy are of paramount importance in such intermediate- and high-risk patients...
Androgen suppression plus radiation therapy for prostate cancerEric M Horwitz
JAMA 292:2084-5; author reply 2085. 2004
MRI-based treatment planning for radiotherapy: dosimetric verification for prostate IMRTLili Chen
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
Int J Radiat Oncol Biol Phys 60:636-47. 2004....
The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapyMark K Buyyounouski
Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 59:1383-91. 2004..Intensity-modulated radiation therapy may offer further reductions in the doses received by the PB and CB; however, at what cost to prostate coverage and normal tissue sparing will be the subject of a follow-up study...
Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancerPeter R Carroll
Department of Urology, University of California School of Medicine, San Francisco, San Francisco, California, USA
Urology 60:1-6. 2002
A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapyDerek B Chism
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111-2497, USA
Int J Radiat Oncol Biol Phys 59:380-5. 2004..CONCLUSIONS: The SF model created prognostic groups with a greater internal consistency than the DF model. The SF was also better at identifying patients with high-risk prostate cancer who may benefit from a more aggressive approach...
Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findingsBenjamin Movsas
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Urology 60:634-9. 2002..The P/M PO2 ratio was the strongest predictor for biochemical control on stepwise multivariate analysis. Longer follow up with more patients is planned to confirm this result...
Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancerCharles J Rosser
Department of Urology, The University of Texas, M.D. Anderson Cancer Center, Houston 77030, USA
J Urol 168:2001-5. 2002..The PSA bounce phenomenon was not predictive of time to biochemical recurrence...
Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancerEugene H Huang
Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Int J Radiat Oncol Biol Phys 54:1314-21. 2002..Therefore, dose escalation may be safely achieved by adherence to dose-volume histogram constraints during treatment planning and organ localization at the time of treatment to ensure consistent patient setup...
The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancerRojymon Jacob
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111-2497, USA
Cancer 100:538-43. 2004..CONCLUSIONS: Escalation of RT dose reduced the rates of BF, DM, and OM significantly in patients with prostate cancer. The inclusion of YOT had a pronounced effect on these correlations that may confound interpretation...
Experience of ultrasound-based daily prostate localizationAnurag Chandra
Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
Int J Radiat Oncol Biol Phys 56:436-47. 2003..Although the accuracy of the BAT was not addressed in this investigation, we found a significant percentage of large shifts being made from the initial alignment position...
Research Grants
- Xenogen IVIS-200 Bioluminescent Imaging SystemAlan Pollack; Fiscal Year: 2007..The information gained will guide researchers in the appropriate use of the therapeutic or preventive agents being studied, and elucidate the roles of specific molecular events in tumor formation and development. ..
